Antibody diversity and specificity and new insights into structure
Antibody diversity and specificity and new insights into structure
2025-04-01
BackgroundThe mysteries surrounding the mechanisms that generate antibody diversity were largely resolved in the 1970s with the discovery of variable gene rearrangement and somatic...
Angptl3 is a key regulator of lipid metabolism
Angptl3 is a key regulator of lipid metabolism
2025-03-31
Angiopoietin-related protein 3 (Angptl3) is a member of the angiopoietin-like protein (ANGPTL) family, also known as Ang-5 Angpt5 is involved in the regulation of lipid and gl...
HIV invades the coreceptor CCR5
HIV invades the coreceptor CCR5
2025-03-28
CC chemokine receptor type 5, also known as CCR5 or CD195, is a protein on the surface of white blood cells that is associated with the immune system because it acts as a receptor ...
B-lymphocyte marker CD19
B-lymphocyte marker CD19
2025-03-28
CD19, a B-lymphocyte antigen (CD19), acts as a co-peptide of the B-cell antigen receptor complex (BCR) on B lymphocytes. CD19 is a biomarker for normal and neoplastic B cells, as w...
Development of bispecific antibody-drug conjugates targeting EpCAM and CLDN3
Development of bispecific antibody-drug conjugates targeting EpCAM and CLDN3
2025-03-27
BackgroundEpithelial cell adhesion molecule (EpCAM), a tumor antigen targeted by antibody-drug conjugates (ADCs), is highly expressed in many epithelial cancers. However, clinical ...
The chemokine receptor CCR4
The chemokine receptor CCR4
2025-03-27
CCR4, also known as CD194 or CMKBR4, is a chemokine receptor. It is a G protein-coupled receptor (GPCR) used for signal transduction, causing cell chemotaxis and activation. CCR4 i...
CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells
CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells
2025-03-25
BackgroundTumor-infiltrating regulatory T cells (TI-Tregs) are key components of the tumor microenvironment (TME) that promote immune evasion and drive tumor progression. Although ...